Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344904 | 0.86 | L3MBTL3 (0.51) | — | |
| SCHEMBL28462797 | 0.85 | P2RY6 (0.45) | ALDH1A1KDM4EHSD17B10ALOX15HPGD | |
| SCHEMBL13664661 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10ALOX15HPGD | |
| SCHEMBL16394331 | 0.82 | LMNA (0.49) | ALDH1A1KDM4EHSD17B10ALOX15HPGD | |
| SCHEMBL2717608 | 0.81 | MAPT (0.47) | ALDH1A1KDM4EHSD17B10ALOX15HPGD | |
| SCHEMBL9424407 | 0.80 | P2RY6 (0.36) | ALDH1A1KDM4EHSD17B10ALOX15HPGD | |
| SCHEMBL5725595 | 0.80 | MAPT (0.45) | ALDH1A1HSD17B10MAPTP2RY6LGMN | |
| SCHEMBL517105 | 0.80 | ADRA2C (0.52) | ALDH1A1KDM4EMAPTKMT2AHTT | |
| SCHEMBL23342230 | 0.79 | MAPT (0.47) | ALDH1A1KDM4EHSD17B10ALOX15HPGD | |
| SCHEMBL5725616 | 0.79 | CHKA (0.50) | ALDH1A1KDM4EMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105330984-A | TPV composition and automobile hand brake grip coating material | ANHUI XIONGYA PLASTIC TECHNOLOGY CO LTD | 2016-02-17 | — | — | CN | claimed |
| US-20250257058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | US GOV VETERANS AFFAIRS (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4508038-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | The United States Government as represented by the Department of Veterans Affairs (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023201374-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-105385011-B | A kind of TPV compositions and automobile collision preventing billot | 嘉兴市博尔塑胶有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-2817310-B1 | 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-21 | — | — | EP | disclosed |
| CN-104114557-B | 8-substituted 2-amino- [1,2,4] triazolo [1,5-a ] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors | 默克专利股份公司 | 2017-10-24 | — | — | CN | disclosed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| CN-105385011-A | TPV composition and automobile anti-collision strip | Jiaxing boer plastic co ltd | 2016-03-09 | — | — | CN | disclosed |
| CN-105330984-A | TPV composition and automobile hand brake grip coating material | ANHUI XIONGYA PLASTIC TECHNOLOGY CO LTD | 2016-02-17 | — | — | CN | disclosed |
| EP-1857446-A1 | NOVEL HSP90 INHIBITOR | Nippon Kayaku Kabushiki Kaisha (JP) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007122241-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040116417-A1 | Thiohydantoins and use thereof for treating diabetes | LABORATOIRES FOURNIER SA (FR) | 2004-06-17 | — | — | US | disclosed |
| CN-1500081-A | Thiohydantonins and use thereof for treating diabetes | ʵ���Ҹ���Ү��˾ | 2004-05-26 | — | — | CN | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | PELI1, MALT1, MCTS1 | ALDH1A1 3322/4885KDM4E 1840/4885HSD17B10 3939/4885 |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | ALDH1A1 1035/4885KDM4E 458/4885HSD17B10 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.